CTX310 Cuts Triglycerides 63% at Day 30 in Severe Hypertriglyceridemia
CRSP is trading near its 52-week low of $44.12 (14% above the low).
Summary
A single course of CTX310 lowered mean triglycerides 63% and ANGPTL3 65% from baseline at Day 30 in 10 Phase 1b patients with severe hypertriglyceridemia, where median baseline triglycerides topped 1,000 mg/dL. No treatment-related serious adverse events were reported, and seven participants have reached at least 90 days of follow-up. The biomarker activity supports target engagement, but the cohort is tiny and the release offers no comparator, so durability and clinical outcomes are still unproven. This is the first hard efficacy readout on CTX310 in the severe-disease setting and comes days after the Q3 update showed CASGEVY revenue of $99M, up 30% quarter over quarter, against a $111.4M quarterly net loss. The company's $2.28B cash pile funds at least 24 months of operations, so this program has room to run. Watch for longer follow-up and any enrollment update from the ongoing U.S. and ex-U.S. Phase 1b trials.
At the time of this announcement, CRSP was trading at $50.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $44.12 to $63.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.